• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs

ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs

by Truveta Research | Aug 23, 2024 | Research, Research Insights

Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
ISPE 2024: Real-world patterns in GLP-1 RA switching from 2018-2023 in the US

ISPE 2024: Real-world patterns in GLP-1 RA switching from 2018-2023 in the US

by Truveta Research | Aug 22, 2024 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
Exploring medication switching trends from Humira to approved biosimilars

Exploring medication switching trends from Humira to approved biosimilars

by Truveta Research | Aug 6, 2024 | Research, Research Insights

Authors: Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
Truveta Research leads first study to explore GLP-1 reinitiation trends and factors

Truveta Research leads first study to explore GLP-1 reinitiation trends and factors

by Truveta Research | Jul 30, 2024 | Research

This study characterized discontinuation and reinitiation of GLP-1 medications for a large population of patients with overweight or obesity who started a GLP-1 medication between 2018-2023. The study also identified factors associated with stopping and subsequently...
Trends in testing and diagnosis of peripheral vascular disease in the US

Trends in testing and diagnosis of peripheral vascular disease in the US

by Truveta Research | Jul 25, 2024 | Research, Research Insights

The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
GLP-1 RA prescription trends: January 2018 – June 2024

GLP-1 RA prescription trends: January 2018 – June 2024

by Truveta Research | Jul 23, 2024 | Research

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%). Month-over-month anti-diabetic medication (ADM) prescribing increased in April and May 2024 then decreased slightly in June...
« Older Entries
Next Entries »

Share this


Recent posts

  • Completing the evidence picture with linked EHR and closed claims data
  • Truveta recognized on national and Seattle LinkedIn Top Startup 2025 lists
  • AI and imaging open new avenues for studying body composition at scale

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.